Loading patent…
AssigneesTecnifar—Industria Tecnica Farmaceutica, S.A., Technophage, InvestigaçãO E Desenvolvimento Em Biotecnologia, SA
InventorsMiguel Ängelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Sara Ferreira Llorente Grancho Lourenço
Estimating the term…
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.
A method of treating or reducing the incidence of a Pseudomonas aeruginosa bacterial infection in a subject in need thereof, said method comprising administering to said subject an effective amount of a pharmaceutical composition comprising a purified bacteriophage having a nucleic acid sequence of SEQ ID NO:3 and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.